{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:08:28Z","timestamp":1794344908074,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In people with chronic obstructive pulmonary disease (COPD) on inhaled corticosteroid\/long-acting \u03b2<jats:sub>2<\/jats:sub>-agonist (ICS\/LABA) therapy, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends stepping up to ICS\/long-acting muscarinic antagonist (LAMA)\/long-acting \u03b22-agonist (LABA) in those with exacerbations or switching to LAMA\/LABA in those with major symptoms. However, the effect of stepping up to ICS\/LAMA\/LABA versus switching to LAMA\/LABA on exacerbation risk is unclear. This analysis evaluated the effect of escalating to ICS\/LAMA\/LABA versus switching to LAMA\/LABA or staying on ICS\/LABA on lung function and exacerbation rates in symptomatic individuals with COPD without a recent exacerbation history from KRONOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In KRONOS (NCT02497001), symptomatic participants with moderate-to-very severe COPD (exacerbations in the prior year were not required for inclusion) were randomized to budesonide\/glycopyrronium\/formoterol fumarate dihydrate 320\/14.4\/10 \u03bcg (BGF), glycopyrronium\/formoterol fumarate dihydrate 14.4\/10 \u03bcg (GFF), budesonide\/formoterol fumarate dihydrate 320\/10 \u03bcg (BFF) via metered-dose inhaler, or budesonide\/formoterol fumarate dihydrate 400\/12 \u03bcg via dry-powder inhaler (BUD\/FORM) for 24 weeks. In participants without a recent exacerbation history on ICS\/LABA in the 30 days before screening, morning pre-dose trough FEV<jats:sub>1<\/jats:sub> change from baseline and moderate\/severe exacerbation rates over 24 weeks were analyzed post-hoc using linear repeated measures models and negative binomial regression, respectively, and participants escalated to ICS\/LAMA\/LABA (BGF) were compared with those switching to LAMA\/LABA (GFF) or staying on ICS\/LABA (BFF or BUD\/FORM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>On stepping up to BGF, least square means (95% confidence interval [CI]) differences for morning pre-dose trough FEV<jats:sub>1<\/jats:sub> change from baseline over 24 weeks was similar versus switching to GFF (12 [\u201321, 44] mL) but greater versus staying on ICS\/LABA (BGF vs. BFF, 106 [64, 148] mL; BGF vs. BUD\/FORM, 55 [12, 97] mL). Moderate\/severe exacerbations were experienced by participants in all treatment arms (BGF, 14.9%; GFF, 24.0%; BFF 17.6%; BUD\/FORM, 21.2%). Exacerbation risk was reduced when stepping up to BGF versus switching to GFF (rate ratio [95% CI]: 0.57 [0.35, 0.94]); rate ratios (95% CI) for BGF versus remaining on ICS\/LABA were 0.93 (0.47, 1.82) with BFF and 0.62 (0.33, 1.18) with BUD\/FORM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>People with symptomatic COPD and no recent exacerbation history previously on ICS\/LABA had reduced exacerbation risk after escalating to ICS\/LAMA\/LABA versus switching to LAMA\/LABA, and improved lung function versus staying on ICS\/LABA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov registry number NCT02497001 (registration date, 7 July 2015).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12931-025-03234-5","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:13:31Z","timestamp":1746706411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid\/long-acting \u03b22-agonist: post-hoc analyses of KRONOS"],"prefix":"10.1186","volume":"26","author":[{"given":"Dave","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Bafadhel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobrawa","family":"Kisielewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Movitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"3234_CR1","unstructured":"AstraZeneca Pharmaceuticals LP. Symbicort highlights of prescribing information. 2010. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021929s021lbl.pdf. [cited May 21, 2024]."},{"key":"3234_CR2","unstructured":"GlaxoSmithKline, ADVAIR DISKUS highlights of prescribing information. 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021077s029lbl.pdf. [cited May 21, 2024]."},{"key":"3234_CR3","doi-asserted-by":"crossref","unstructured":"Athanazio RA, Bernal Villada L, Avdeev SN, Wang HC, Ramirez-Venegas A, Sivori M et al. Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS international study. BMJ Open Respir Res. 2024;11.","DOI":"10.1136\/bmjresp-2023-002101"},{"key":"3234_CR4","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 Report). 2023. Available from: https:\/\/goldcopd.org\/archived-reports\/. [cited March 11, 2024]."},{"key":"3234_CR5","unstructured":"2024 GOLD Global Initiative for Chronic Obstructive Lung Disease, Report. Global Strategy for Prevention, Diagnosis and Management of COPD. 2024. Available from: https:\/\/goldcopd.org\/2024-gold-report\/. [cited 17 September 2024]."},{"key":"3234_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35\u201348.","journal-title":"N Engl J Med"},{"key":"3234_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"},{"key":"3234_CR8","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2025 GOLD report: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025. Available from: https:\/\/goldcopd.org\/2025-gold-report\/ [cited 7 February 2025]."},{"key":"3234_CR9","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.2147\/COPD.S137872","volume":"12","author":"M Calle Rubio","year":"2017","unstructured":"Calle Rubio M, Casamor R, Miravitlles M. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD guidelines: the FENEPOC study. Int J Chron Obstruct Pulmon Dis. 2017;12:2373\u201383.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3234_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1378\/chest.08-2062","volume":"135","author":"P-R Burgel","year":"2009","unstructured":"Burgel P-R, Nesme-Meyer P, Chanez P, Caillaud D, Carr\u00e9 P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975\u201382.","journal-title":"Chest"},{"key":"3234_CR11","doi-asserted-by":"publisher","first-page":"e85540","DOI":"10.1371\/journal.pone.0085540","volume":"9","author":"H Mullerova","year":"2014","unstructured":"Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS ONE. 2014;9:e85540.","journal-title":"PLoS ONE"},{"key":"3234_CR12","doi-asserted-by":"publisher","first-page":"106921","DOI":"10.1016\/j.rmed.2022.106921","volume":"200","author":"R Hughes","year":"2022","unstructured":"Hughes R, Rapsomaniki E, Janson C, Keen C, Make BJ, Burgel PR, et al. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and\/or COPD in the NOVELTY study. Respir Med. 2022;200:106921.","journal-title":"Respir Med"},{"key":"3234_CR13","doi-asserted-by":"crossref","unstructured":"Reddel HK, Vestbo J, Agusti A, Anderson GP, Bansal AT, Beasley R et al. Heterogeneity within and between physician-diagnosed asthma and\/or COPD: NOVELTY cohort. Eur Respir J. 2021;58.","DOI":"10.1183\/13993003.03927-2020"},{"key":"3234_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20:238.","journal-title":"Respir Res"},{"key":"3234_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747\u201358.","journal-title":"Lancet Respir Med"},{"key":"3234_CR16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202406-1254CI","author":"D Singh","year":"2024","unstructured":"Singh D, Han MK, Bhatt SP, Miravitlles M, Compton C, Kolterer S, et al. Is disease stability an attainable COPD treatment goal? Am J Respir Crit Care Med. 2024. https:\/\/doi.org\/10.1164\/rccm.202406-1254CI","journal-title":"Am J Respir Crit Care Med"},{"key":"3234_CR17","doi-asserted-by":"publisher","first-page":"e006171","DOI":"10.1136\/bmjopen-2014-006171","volume":"4","author":"H M\u00fcllerov\u00e1","year":"2014","unstructured":"M\u00fcllerov\u00e1 H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4:e006171.","journal-title":"BMJ Open"},{"key":"3234_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","volume":"23","author":"JR Hurst","year":"2022","unstructured":"Hurst JR, Han MK, Singh B, Sharma S, Kaur G, de Nigris E, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022;23:213.","journal-title":"Respir Res"},{"key":"3234_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/COPD.S346591","volume":"17","author":"H Whittaker","year":"2022","unstructured":"Whittaker H, Rubino A, Mullerova H, Morris T, Varghese P, Xu Y, et al. Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK routine health care data study. Int J Chron Obstruct Pulmon Dis. 2022;17:427\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3234_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/COPD.S406007","volume":"18","author":"JJ Soler-Catalu\u00f1a","year":"2023","unstructured":"Soler-Catalu\u00f1a JJ, Izquierdo JL, Ju\u00e1rez Campo M, Sicras-Mainar A, Nuevo J. Impact of COPD exacerbations and burden of disease in Spain: AVOIDEX study. Int J Chron Obstruct Pulmon Dis. 2023;18:1103\u201314.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3234_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12931-023-02601-4","volume":"24","author":"KMA Swart","year":"2023","unstructured":"Swart KMA, Baak BN, Lemmens L, Penning-van Beest FJA, Bengtsson C, Lobier M, et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO data network in the Netherlands. Respir Res. 2023;24:293.","journal-title":"Respir Res"},{"key":"3234_CR22","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/COPD.S139470","volume":"12","author":"DM Halpin","year":"2017","unstructured":"Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891\u2013908.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3234_CR23","doi-asserted-by":"publisher","first-page":"175346662211073","DOI":"10.1177\/17534666221107314","volume":"16","author":"D Singh","year":"2022","unstructured":"Singh D, Hurst JR, Martinez FJ, Rabe KF, Bafadhel M, Jenkins M, et al. Predictive modeling of COPD exacerbation rates using baseline risk factors. Ther Adv Respir Dis. 2022;16:17534666221107314.","journal-title":"Ther Adv Respir Dis"},{"key":"3234_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/COPD.S286087","volume":"16","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, et al. Budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler improves exacerbation outcomes in patients with COPD without a recent exacerbation history: a subgroup analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021;16:179\u201389.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3234_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15412555.2021.1977789","volume":"19","author":"S Suissa","year":"2022","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD. 2022;19:1\u20139.","journal-title":"COPD"},{"key":"3234_CR26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285\u201394.","journal-title":"N Engl J Med"},{"key":"3234_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203:553\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"3234_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175:1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03234-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:57:58Z","timestamp":1748239078000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03234-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03234-5","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The license text has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The KRONOS study was conducted in accordance with Good Clinical Practice, including the Declaration of Helsinki. The study protocol and informed consent forms were approved by appropriate institutional review boards or independent ethics committees (see [] for a complete listing). All patients provided written informed consent before screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dave Singh reports personal fees from Adovate, Aerogen, Almirall, Apogee, Arrowhead, AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CONNECT Biopharm, Covis, CSL Behring, DevPro Biopharma LCC, Elpen, Empirico, EpiEndo, Genentech, Generate Biomedicines, GlaxoSmithKline, Glenmark, Kamada, Kinaset Therapeutics, Kymera, Menarini, MicroA, OM Pharma, Orion, Pieris Pharmaceuticals, Pulmatrix, Revolo, Roivant Sciences, Sanofi, Synairgen, Tetherex, Teva, Theravance Biopharma, Upstream and Verona Pharma. Mona Bafadhel reports grants to her institution from AstraZeneca, and honoraria to her institution from AstraZeneca, Chiesi, and GlaxoSmithKline; and is on the scientific advisory board for Albus Health and ProAxsis. Niki Arya, Jonathan Marshall, Dobrawa Kisielewicz, Charlotta Movitz, Karin Bowen and Mehul Patel are employees of AstraZeneca and hold stock and\/or stock options in the company. Himanshu Parikh is a former employee of AstraZeneca and holds stock and\/or stock options in the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"These data have been presented in part at the 2023 European Respiratory Society International Congress, (Milan, Italy; 9\u201313 September 2023) as a poster, with the associated published abstract (Eur Respir 62: PA4687; ).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior publication"}}],"article-number":"175"}}